Download PDF
Thromb Haemost 1995; 74(01): 437-439
DOI: 10.1055/s-0038-1642717
Symposium
Management of Haemophilias
Schattauer GmbH Stuttgart

Effects of Factor VIII Concentrates on the Immune System of Patients with Hemophilia

Pier Mannuccio Mannucci
“Angelo Bianchi Bonomi” Hemophilia and Thrombosis Center and Institute of Internal Medicine, University of Milan, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Mannucci PM. Modem treatment of hemophilia: from the shadows towards the light. Thromb Haemostas 1993; 70: 17-22
    PubMedGoogle Scholar
  • 2 Kasper CK, Lusher JM. and the Transfusion Practice Committee. Recent evaluation of clotting factor concentrates forhemohilia A and B Transfusion 1993; 33: 422-433
    CrossrefPubMed
  • 3 Bemtorp E. Impact of replacement therapy cm the evaluation of HIV infection in hemophiliacs. Thromb Haemostas 1994; 71: 678-683
    PubMedGoogle Scholar
  • 4 Gjerset GF, Pike MC, Mosley JW, Hassett J, Fletcher MA, Donegan E, Parker JW, Counts RB, Zhov Y, Kasper C. Operskalski EA and the Transfusion Safety Study. Effect of low - and intermediate - purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders Blood 1994; 84: 1666-1671
    PubMedGoogle Scholar
  • 5 de Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized prospective two year conparison with an intermediate purity concentrate. Blood 1991; 78: 1918-1922
    PubMedGoogle Scholar
  • 6 Seremitis S, Aledort LM, Bergman G, Bona R, Bray G, Brettler DB, Eyster ME, Kessler C, Lan TS, Lusher JM, Rickerls F. Three-year randomized study of high-purity or intermediate purity factor VIII concentrates in symptom-free HIV- seropositive hemophiliacs: effects on immune status. Lancet 1993; 342: 700-703
    CrossrefPubMedGoogle Scholar
  • 7 Mannucci PM, Brettler DB, Aledort LM, Hurst D, Schwartz RS, Lusher JM. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. Blood 1994; 83: 1958-1962
    PubMedGoogle Scholar
  • 8 Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIII :C concentrate purified from plasma using monoclonal antibodies: human studies. Blood 1989; 73: 1859-1963
    PubMedGoogle Scholar
  • 9 Goldsmith JM, Deutsche J, Tany M, Green D. CD4 cells in HIV-1 infected hemophiliacs effect of factor VIII concentrates. Thromb Haemostas 1991; 66: 415-419
    PubMedGoogle Scholar
  • 10 Hilgartner M, Buckley JD, Operskaski EA, Pike MC, Mosley JW. Purity of factor VIII concentrates and serial CD4 counts. Lancet 1993; 341: 1373-1374
    CrossrefPubMedGoogle Scholar
  • 11 Goedert JJ, Cohen AR, Kessler CM, Eichenger S, Seremetis SV, Rabkin CS, Yellin FJ, Rosenberg PS, Aledort LM. Risks of immunodeficiency, AIDS and death related to purity of factor VIII concentrates. Lancet 1994; 344: 791-792
    CrossrefPubMedGoogle Scholar
  • 12 Varon G, Shulman S, Dardik R, Barzilai A. Martinowitz High versus ultra-high purity factor VIII concentrate therapy: prospective evaluation of immunobiological and clinical parameters in HIV seronegative and seropositive hemophiliacs. Thromb Haemostas 1994; 72: 359-362
    PubMedGoogle Scholar
  • 13 Aledort L. Inhibitors in hemophilia patients: current status and management. An J Hematol 1994; 47: 208-217
    PubMedGoogle Scholar
  • 14 Lusher JM, Arkin S, Abildgaard CF. Schwartz RS and the Kogenate Previously Untreated Patients Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A N Engl J Med 1993; 328: 453-547
    CrossrefPubMedGoogle Scholar
  • 15 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M. A multicenter study of recombinant factor VIII (Recombinate). Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A Blood 1994; 83: 2428-2437
    PubMedGoogle Scholar
  • 16 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gunga T, Krackhardt B, Kcmhuber B. Incidence of developement of factor VIII and factor IX inhibitors in hemophiliacs. Lancet 1992; 339: 594-598
    CrossrefPubMedGoogle Scholar
  • 17 Addiego J, Kasper C, Abildgaard CF, Hilgartner M, Lusher JM, Glader B, Aledort L. Frequency of inhibitor development in hemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-464
    CrossrefPubMedGoogle Scholar
  • 18 Peerlinck K, Amout J, Gilles JC, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfued hemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemostas 1993; 69: 115-118
    PubMedGoogle Scholar
  • 19 Rosendaal FR, Niewenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PF W. Brief E and the Dutch Hemophilia Group. A sudden increase in factor VIII inhibitor developement in multitransfused hemophilia A patients in the Netherlands Blood 1993; 81: 2180-2186
    PubMedGoogle Scholar